Table 6.
Comparison of availability of diabetes medicines.
| Medicines | Availability of LPGs (No. of studies)a | Current study |
|---|---|---|
| Metformin 500 and 850 mg cap/tab | 76.7% (n = 23) | 70.97% |
| Insulin human, soluble, isophane and 30/70, 100 IU/ml vial | 30.0% (n = 9) | 26.0% |
| Gliclazide 80 mg cap/tab | 13.3% (n = 4) | 46.0% |
a
Ewen M, Zweekhorst M, Regeer B, Laing R (2017) Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS ONE 12(2): e0171284.